1. Introduction {#sec0005}
===============

In the cardiovascular system, exposure to arsenic accelerates the development of atherosclerosis and predisposes to hypertension and peripheral microvascular abnormalities such as Blackfoot Disease ([@bib0005; @bib0215; @bib0175]). Underlying mechanisms have been suggested to involve increased oxidant stress, because exposure of endothelial cells to arsenite at concentrations within the range found in contaminated drinking water (0.3--15 μM) causes excess production of the superoxide anion (O~2~^•−^) by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase ([@bib0010; @bib0170; @bib0150; @bib0180]). O~2~^•−^ may contribute to vascular dysfunction through a rapid interaction with, and inactivation of, the potent vascular relaxing factor endothelium-derived nitric oxide (NO) ([@bib0110]). Dismutation of O~2~^•−^ by superoxide dismutase (SOD) also generates hydrogen peroxide (H~2~O~2~), and the production of both reactive oxygen species (ROS) increases within minutes of exposing endothelial cells to low concentrations of arsenite (5 μM) ([@bib0010; @bib0170]). Notably, endothelium-derived H~2~O~2~ is now thought to participate in the physiological response to endothelium-dependent agonists and fluid shear stress ([@bib0130; @bib0125]), and can compensate for the loss of NO bioavailability observed in experimental models of hypertension and diabetes and in patients with arterial disease ([@bib0095; @bib0100; @bib0140; @bib0105]). One possible mode of action may be an ability of H~2~O~2~ to relax subjacent smooth muscle cells by acting as a freely diffusible endothelium-derived hyperpolarizing factor (EDHF) ([@bib0130; @bib0125]). However, H~2~O~2~ may also promote depletion of the endothelial endoplasmic reticulum (ER) Ca^2+^ store and amplify increases in cytosolic Ca^2+^ evoked by pharmacological stimulation of the endothelium ([@bib0080; @bib0045]). This synergy can enhance the opening of calcium-activated K^+^ channels (K~Ca~) thereby allowing H~2~O~2~ to potentiate "EDHF-type" relaxations that are mediated by the spread of endothelial hyperpolarization into the arterial media *via* myoendothelial and homocellular smooth muscle gap junctions ([@bib0045; @bib0060]). Recently it has been reported that EDHF-type responses to the endocannabinoid-like molecule N-oleoylethanolamine are modulated by H~2~O~2~ ([@bib0205]).

The aim of the current study was to investigate how inorganic As^III^, which is intrinsically more toxic than inorganic As^V^ ([@bib0195]), affects EDHF-type and NO-mediated relaxations *via* the generation of O~2~^•−^ and H~2~O~2~. Endothelium-dependent relaxations of rabbit iliac artery (RIA) and aortic rings were elicited by the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca^2+^ entry by depleting ER Ca^2+^ by inhibiting the endothelial SERCA pump ([@bib0055]). In the RIA such relaxations consist of dual NO-mediated and EDHF-type gap junction-dependent components ([@bib0070; @bib0065; @bib0025]), whereas in the aorta the EDHF-type component is negligible, so that the two mechanisms of relaxation can be dissociated ([@bib0165; @bib0055]). The effects of arsenite were compared in the presence and absence of endogenous NO production, and the functional role of H~2~O~2~ investigated with catalase and a manganese-based SOD/catalase mimetic ([@bib0035]). The role of NADPH oxidase was investigated with apocynin, which blocks the assembly of specific forms of this enzyme, and prevents the generation of O~2~^•−^ and H~2~O~2~ in cultured endothelial cells treated with arsenite ([@bib0010; @bib0185]). Dihydroethidium (DHE) was used to assess ROS production in the different layers of the arterial wall ([@bib0210]).

2. Methods {#sec0010}
==========

2.1. Mechanical responses {#sec0015}
-------------------------

Iliac arteries, aortae and aortic valve leaflets (RAV) were obtained from male NZW rabbits (2--2.5 kg) killed by injection of sodium pentobarbital (150 mg/kg; i.v.) *via* the marginal ear vein and in accordance with local University guidelines. Rings of iliac artery or aorta 2--3 mm wide were mounted in a myograph (model 610M, Danish Myotechnology, Aarhus, Denmark) containing oxygenated (95% O~2~; 5% CO~2~) Holman\'s buffer (composition in mM: NaCl 120, KCl 5, NaH~2~PO~4~ 1.3, NaHCO~3~ 25, CaC1~2~ 2.5, glucose 11, and sucrose 10) at 37 °C and maintained at a resting tension of 1 mN over a 60 min equilibration period, with frequent readjustments in baseline tension to correct for stress relaxation. To evaluate EDHF-type responses, preparations were incubated for 30 min with the eNOS inhibitor N^G^-nitro-[L]{.smallcaps}-arginine methyl ester ([L]{.smallcaps}-NAME, 300 μM) and the cyclooxygenase inhibitor indomethacin (10 μM) to inhibit prostanoid formation. Sodium arsenite (30 or 100 μM) was then added for 30 or 90 min prior to constriction with phenylephrine (PE, 1 μM). Once constrictor responses had reached a stable plateau, relaxation was studied by constructing cumulative concentration--response curves to CPA or ACh in the continued presence of arsenite. These curves were generally completed within ∼60 min so that total cumulative exposure to arsenite was 90 min and 150 min in the two protocols. Preliminary experiments demonstrated that lower concentrations of arsenite (10 μM) did not affect relaxation under these experimental conditions. To evaluate the role of O~2~^•−^ and H~2~O~2~, catalase (2000 units/ml, from bovine liver), manganese(III) tetrakis (1-methyl-4-pyridyl) porphyrin (MnTMPyP, 100 μM) or the NADPH oxidase inhibitor apocynin (1-(4-hydroxy-3-methoxyphenyl)ethanone, 100 μM) were co-administered with [L]{.smallcaps}-NAME and indomethacin.

2.2. Detection of superoxide/hydrogen peroxide {#sec0020}
----------------------------------------------

RAV leaflets, and endothelium-denuded rings of iliac artery and aorta were incubated with arsenite (100 μM), apocynin (100 μM) or both for 60 min in oxygenated Holman\'s buffer containing [L]{.smallcaps}-NAME (300 μM) and indomethacin (10 μM) at 37 °C. To assess the production of reactive oxygen species (ROS) dihydroethidium (DHE, 5 μM) was then added for a further 30 min, following which the preparations were washed and fixed in 4% paraformaldehyde and images collected with a Leica SP5 confocal microscope (excitation 514 nm, emission 560--630 nm). This protocol was designed to match the total exposure of rings preincubated with 100 μM arsenite for 30 min in mechanical experiments in which it took a further ∼60 min to construct full concentration--relaxation curves. It should be noted that oxidation of DHE can generate two products, ethidium and 2-hydroxyethidium, which possess overlapping emission spectra and whose fluorescence is enhanced by binding to DNA ([@bib0210]). Although H~2~O~2~ does not oxidize DHE directly and the formation of 2-hydroxyethidium is specific for O~2~^•−^, H~2~O~2~ may promote the formation of ethidium in the presence of peroxidase activity or haem proteins so that increased fluorescence in DHE-loaded vascular smooth muscle/endothelial cells may reflect production of both O~2~^•−^ and H~2~O~2~ ([@bib0050; @bib0155]). The RAV was used to circumvent the complicating effects of signals transmitted from subjacent smooth muscle to the endothelium. All imaging data presented were acquired in the presence of [L]{.smallcaps}-NAME in order to avoid potentially confounding effects of NO which has been reported to promote the formation of ethidium in the presence of molecular oxygen ([@bib0210]).

2.3. Statistics {#sec0025}
---------------

The maximal percentage reversal of PE-induced tone (*R*~max~) by CPA or ACh and concentrations giving 50% reversal of this constrictor response (IC~50~ for CPA) or 50% of maximal relaxation (EC~50~ for ACh) were determined for each experiment. The use of IC~50~ rather than EC~50~ was necessary to allow for small initial constrictor responses to CPA that were observed in many experiments and can be attributed to an effect of CPA on smooth muscle Ca^2+^ stores ([@bib0025]). All metrics are given as mean ± SEM and compared using paired or unpaired Student\'s *t*-tests or one-way ANOVA followed by a Bonferroni\'s post-test as appropriate. Significance was accepted at *P* \< 0.05; *n* denotes the number of animals studied in each experimental group.

2.4. Reagents {#sec0030}
-------------

Pharmacological agents were purchased from Sigma--Aldrich (UK), except CPA (Ascent Scientific) and MnTMPyP (Calbiochem), and were dissolved in Holman\'s buffer, except apocynin and indomethacin (absolute ethanol), and CPA and DHE (DMSO).

3. Results {#sec0035}
==========

3.1. Effects of arsenite on responses to CPA and ACh in the RIA {#sec0040}
---------------------------------------------------------------

### 3.1.1. EDHF-type relaxations {#sec0045}

Responses evoked by CPA in the presence of [L]{.smallcaps}-NAME/indomethacin were unaffected by exposure to 30 μM arsenite for 30 min, whereas exposure to 100 μM arsenite for 30 min caused a leftward shift in the concentration--relaxation curve, such that pIC~50~ increased from ∼4.8 to ∼5.2 without change in *R*~max~ ([Fig. 1](#fig0005){ref-type="fig"}A; [Table 1](#tbl0005){ref-type="table"}). EDHF-type relaxations evoked by ACh were similarly potentiated by exposure to 100 μM arsenite for 30 min, exhibiting a significant increase in pEC~50~ from ∼6.8 to ∼7.0 without change in *R*~max~ ([Fig. 1](#fig0005){ref-type="fig"}B; [Table 1](#tbl0005){ref-type="table"}).

### 3.1.2. EDHF-type/NO-mediated relaxations {#sec0050}

In control rings with intact endothelium incubated in the absence of [L]{.smallcaps}-NAME/indomethacin, the additional contribution of NO to CPA- and ACh-evoked relaxations was evidenced by pIC~50~ values of ∼5.0 and ∼7.3, and increases in *R*~max~ to ∼90% from ∼80% and ∼70% compared to the corresponding EDHF-type concentration--relaxation curves ([Table 1](#tbl0005){ref-type="table"}). Responses to CPA and ACh were unaffected by incubation with 100 μM arsenite for 30 min ([Fig. 2](#fig0010){ref-type="fig"}A and B; [Table 1](#tbl0005){ref-type="table"}).

### 3.1.3. Contraction {#sec0055}

In control rings incubated in the absence of [L]{.smallcaps}-NAME/indomethacin, the magnitude of the constrictor response to 1 μM PE was unaffected by exposure to 30 μM arsenite for 30 min, but was reduced by ∼15% following exposure to 100 μM arsenite for 30 min (from 30.1 ± 1.7 mN to 26.7 ± 1.8 mN, pooled data from all experiments *n* = 21, *P* \< 0.01). Incubation with [L]{.smallcaps}-NAME/indomethacin increased PE-induced constriction by ∼15% and this increment in tone was reversed by exposure to 100 μM arsenite for 30 min (from 35.3 ± 1.2 mN to 30.0 ± 1.1 mN, pooled data from all experiments *n* = 73, *P* \< 0.01), such that constriction then matched the level observed in the absence of [L]{.smallcaps}-NAME/indomethacin. No attempt was made to correct for these small overlapping effects on pre-relaxation tone.

3.2. Effects of arsenite on NO-mediated aortic relaxation {#sec0060}
---------------------------------------------------------

Maximal relaxations evoked by CPA and ACh in aortic rings with intact endothelium were equivalent to ∼70% of PE-induced tone and were mediated by NO because no significant EDHF-type component was evident in the presence of [L]{.smallcaps}-NAME/indomethacin ([Fig. 3](#fig0015){ref-type="fig"}A). *R*~max~ and pIC~50~/pEC~50~ values for concentration--relaxation curves constructed for CPA and ACh were unaffected by incubation with 100 μM arsenite for 30 min ([Table 2](#tbl0010){ref-type="table"}). As in the RIA, this incubation protocol reduced PE-induced constriction by ∼15% (from 26.9 ± 1.6 mN to 22.9 ± 1.3 mN, pooled data from all experiments *n* = 14, *P* \< 0.01).

3.3. Effects of catalase, manganese porphyrin and apocynin on EDHF-type responses to CPA in the RIA {#sec0065}
---------------------------------------------------------------------------------------------------

To investigate the mechanisms responsible for the selective potentiation of relaxations elicited in the presence of [L]{.smallcaps}-NAME/indomethacin, rings were preincubated with 2000 units/ml catalase, 100 μM MnTMPyP or 100 μM apocynin ([Fig. 4](#fig0020){ref-type="fig"}). None of these agents alone significantly affected pIC~50~ and *R*~max~ values for relaxation in the absence of arsenite, whereas the enhancement of relaxation observed following exposure to 100 μM arsenite for 30 min was fully prevented in each case ([Table 3](#tbl0015){ref-type="table"}).

3.4. Fluorescence imaging of ROS production {#sec0070}
-------------------------------------------

Exposure to 100 μM arsenite for 90 min significantly enhanced endothelial nuclear fluorescence in RAV leaflets loaded with DHE in the presence of [L]{.smallcaps}-NAME/indomethacin, an effect that was fully prevented by preincubation with 100 μM apocynin ([Fig. 5](#fig0025){ref-type="fig"}). Exposure to 100 μM arsenite for 90 min did not increase fluorescence in either the media or adventitia of endothelium-denuded RIA and aortic rings loaded with DHE ([Fig. 6](#fig0030){ref-type="fig"}).

3.5. Effects of longer term exposure to arsenite {#sec0075}
------------------------------------------------

Exposure to 100 μM arsenite for 90 min caused a ∼30% reduction in force development in RIA rings constricted by 1 μM PE from 33.9 ± 2.9 mN to 23.5 ± 2.6 mN (*n* = 26 and 20) in the presence of [L]{.smallcaps}-NAME/indomethacin and from 30.9 ± 5.4 mN to 22.4 ± 5.3 mN (*n* = 9 and 9) in control rings (pooled data from [Fig. 7](#fig0035){ref-type="fig"}; *P* \< 0.01 in each case). This large depressor effect affected the analysis of endothelium-dependent relaxation, because absolute tension ultimately converged to a similar plateau in the presence and absence of arsenite at the highest concentrations of ACh. Consequently, normalization to initial pre-relaxation tone led to an apparent decrease in *R*~max~ on a % basis ([Fig. 7](#fig0035){ref-type="fig"}A and B), whereas pEC~50~ values derived from the concentration--relaxation curves were unaffected by arsenite ([Table 4](#tbl0020){ref-type="table"}).

Similar experiments demonstrated that exposure to 100 μM arsenite for 90 min also impaired smooth muscle relaxations to the exogenous NO donor MAHMA NONOate in endothelium-intact RIA rings incubated with [L]{.smallcaps}-NAME/indomethacin. The use of an exogenous NO donor excludes any potential effect of arsenite on the NO synthase pathway. Again this incubation protocol did not statistically affect pEC~50~ values derived from concentration--relaxation curves, whereas *R*~max~ was reduced ([Fig. 7](#fig0035){ref-type="fig"}C; [Table 4](#tbl0020){ref-type="table"}).

Experiments were also performed in which the relaxant effects of arsenite on pre-relaxation tone were mimicked by reducing the concentration of PE used to induce constriction to 0.1 μM ([Fig. 7](#fig0035){ref-type="fig"}C). *R*~max~ and pEC~50~ values for MAHMA NONOate were then larger than in experiments conducted in the presence of 1 μM PE or 1 μM PE plus 100 μM arsenite, as complete relaxation was obtained in the presence of the lower concentration of 0.1 μM PE ([Fig. 7](#fig0035){ref-type="fig"}; [Table 4](#tbl0020){ref-type="table"}).

4. Discussion {#sec0080}
=============

The present study has provided new insights into the mechanisms through which short-term exposure to inorganic arsenic can modulate endothelial, and therefore vascular, function. Arsenite was shown to potentiate EDHF-type relaxations by stimulating endothelial NADPH oxidase activity and thereby promoting the formation of H~2~O~2~ from O~2~^•−^, whereas relaxations mediated by endothelium-derived NO were unaffected.

4.1. Potentiating effects of arsenite on the EDHF phenomenon {#sec0085}
------------------------------------------------------------

Arsenite amplified EDHF-type relaxations evoked by the SERCA inhibitor CPA in RIA rings in a concentration-dependent manner, with potentiation being apparent following exposure to 100 μM, but not 30 μM, arsenite for 30 min. This potentiation was prevented by catalase and the catalase/SOD mimetic MnTMPyP, thus confirming a central role for endogenously generated H~2~O~2~. Enhanced relaxation was also prevented by apocynin, and this NADPH oxidase inhibitor abolished arsenite-induced increases in fluorescence in RAV leaflets loaded with the ROS sensitive probe DHE. Arsenite similarly enhanced EDHF-type relaxations to ACh, although this effect was less prominent than with CPA, consistent with previous observations that exogenous H~2~O~2~ amplifies EDHF-type relaxations to ACh at a higher threshold compared with CPA ([@bib0060]). Taken together, these findings indicate that excess O~2~^•−^ generated by the activation of endothelial NADPH oxidase by arsenite can serve as a source of H~2~O~2~ that modulates the EDHF phenomenon. Previous analysis has demonstrated that exogenous H~2~O~2~ synergistically enhances depletion of the ER Ca^2+^ store by CPA and amplifies electrotonically conducted relaxations by promoting endothelial K~Ca~ channel opening ([@bib0045; @bib0060]). The present study extends these observations by demonstrating that endogenously generated H~2~O~2~ can enhance the biological role of the EDHF phenomenon under conditions of increased oxidative stress.

The classical phagocytic NADPH oxidase comprises a membrane-bound flavocytochrome b~558~ component constructed from a catalytic Nox subunit (designated as Nox2 or gp91phox) and a p22phox regulatory subunit. p22phox co-activation requires translocation of additional protein subunits (p47phox, p67phox, p40phox and the small GTPase Rac1) to the cell membrane where they associate with the b~558~ heterodimer in a cascade that can be interrupted by apocynin at the level of p47phox ([@bib0160; @bib0185; @bib0110]). Exposure to arsenite increases the overall Nox catalytic activity of membrane fractions from cultured intact endothelial cells by twofold within 1 h, whereas treatment of isolated endothelial membranes is without effect ([@bib0170]). More specifically, the ability of arsenite to stimulate endothelial O~2~^•−^ production has an obligatory requirement for gp91phox, p47phox and p67phox and Rac1, consistent with activation of the Nox2-based oxidase ([@bib0170; @bib0150; @bib0180]). It should be noted that the Nox2-based oxidase can also be detected in a perinuclear distribution where it is associated with the endothelial cytoskeleton and might contribute to intracellular O~2~^•−^ production directly ([@bib0160]). Other Nox homologues are also expressed in the arterial wall, with the dominant subtypes found in large arteries being Nox2 and Nox4 in the endothelium and Nox1 and Nox4 in smooth muscle ([@bib0020; @bib0110]). In contrast to Nox2, the Nox4 homologue is constitutively active, localizes to the endoplasmic/sarcoplasmic reticulum, generates H~2~O~2~ in preference to O~2~^•−^, and is insensitive to apocynin because catalytic activity depends on Nox4/p22phox without the requirement for p47phox and other proteins that characterizes the phagocytic complex ([@bib0020; @bib0030; @bib0040; @bib0155]). The present findings therefore imply that the Nox4-based oxidase does not contribute to the potentiating effects of arsenite, as EDHF-type relaxations were fully blocked by apocynin. While it has been suggested that apocynin might act as an antioxidant rather than an inhibitor of NADPH oxidase, the antioxidant effects were detected only at 1 mM and were absent at the 100 μM apocynin concentration employed in the present study ([@bib0085]).

4.2. Differential effects of arsenite on EDHF-type and NO-mediated relaxations {#sec0090}
------------------------------------------------------------------------------

Activation of endothelial NADPH oxidase should in theory impair NO-mediated arterial relaxations as a consequence of the reaction between O~2~^•−^ and NO ([@bib0075]), whose existence following exposure to arsenite has been inferred from evidence of tissue protein nitrosation, presumably by peroxynitrite, in endothelial cells ([@bib0180]). However, we found that arsenite did not affect aortic relaxations evoked by CPA and ACh, even though such responses were mediated exclusively by NO, and arsenite was confirmed to stimulate ROS production in the RAV endothelium. Furthermore, while arsenite potentiated EDHF-type relaxations, no evidence of potentiation was evident in the absence of [L]{.smallcaps}-NAME/indomethacin. Taken together, these observations suggest (i) that the flux of NO generated by CPA or ACh substantially exceeds the rate of formation of O~2~^•−^ induced by arsenite in rabbit endothelial cells, and (ii) that NO may limit the availability of O~2~^•−^ for dismutation to H~2~O~2~, thereby compromising the ability of arsenite to potentiate any co-existent EDHF-type component of relaxation. Notably, we also demonstrated that arsenite did not enhance ROS generation in the media of the RIA or aorta, and this is likely to explain its inability to impair NO-mediated relaxation, despite increased ROS production by the endothelium. In this regard it should be noted that selective increases in endothelial O~2~^•−^ production also fail to impair NO-mediated aortic relaxations to ACh or nitroprusside in transgenic mice with targeted endothelial overexpression of Nox2 ([@bib0015]), and that overexpression of Nox4 in the endothelium, to increase intracellular production of H~2~O~2~ (but not O~2~^•−^) may enhance EDHF-type relaxations in transgenic mice without altering NO bioavailability ([@bib0155]). By contrast, the well-documented ability of angiotensin II to depress NO-mediated endothelium-dependent relaxation is accompanied by a global increase in ROS production across the vessel wall secondary to dual activation of the Nox1-based smooth muscle oxidase and the Nox2-based endothelial oxidase ([@bib0115; @bib0190; @bib0110]). Angiotensin II may also stimulate ROS generation by vascular adventitial cells ([@bib0135]), whereas no evidence for excess arsenite-induced adventitial DHE fluorescence was apparent in the present study.

4.3. Relationship with previous studies {#sec0095}
---------------------------------------

Previous reports have provided evidence that chronic *in vivo* exposure to inorganic arsenic can impair subsequent *ex vivo* endothelium-dependent relaxations to ACh in the rabbit and the rat aorta ([@bib0145; @bib0200]). While these studies hypothesized that impaired NO-mediated relaxations reflected overproduction of O~2~^•−^, the measurements made were indirect (plasma \[H~2~O~2~\], nitrite and cGMP levels), and assessment of ROS production in the vessel wall was not attempted. [@bib0120] also observed apparent reductions in endothelium-dependent relaxations to ACh in rat aortic rings exposed to 50 μM arsenite for 14 h, but attributed these to impaired cGMP-mediated mechanisms of relaxation and impaired conversion of [L]{.smallcaps}-arginine to [L]{.smallcaps}-citrulline by eNOS, rather than increased ROS production. In view of these conflicting observations, we evaluated the effects of more prolonged 90 min incubation with arsenite on both EDHF-type and NO-mediated relaxation evoked by ACh in RIA rings. Notably, this protocol reduced the contractile response to 1 μM PE by ∼30%, both in the presence or absence of [L]{.smallcaps}-NAME/indomethacin, without greatly affecting the residual level of tone observed at the point of maximal ACh-induced relaxation, so that standard analysis led to an apparent decrease in *R*~max~, calculated on a % basis relative to the initial level of pre-relaxation tone. However, pEC~50~ values for the corresponding concentration--relaxation curves were not affected by arsenite, and were essentially unchanged compared to those obtained after exposure to 100 μM arsenite for 30 min. We observed a similar phenomenon in experiments where direct smooth muscle relaxation was elicited with MAHMA NONOate after constriction by 1 μM PE and arsenite again reduced *R*~max~ but not pEC~50~ values. By contrast, when tone was induced by 0.1 μM PE, to match the depressed constriction observed with 1 μM PE in the presence of arsenite, the reversal of tone by MAHMA NONOate was essentially complete. Taken together, such observations suggest that apparent reductions in *R*~max~ in the presence of arsenic primarily reflect a generalized impairment of smooth muscle function, rather than specific effects against EDHF-type and NO-mediated relaxations.

5. Conclusion {#sec0100}
=============

The present study has identified complex effects of short-term exposure to inorganic arsenic on EDHF-type and NO-mediated arterial relaxations. An ability of arsenite to increase endothelial production of H~2~O~2~ secondary to activation of NADPH oxidase can potentiate EDHF-type responses, whereas selective increases in endothelial O~2~^•−^ production appeared insufficient to impair smooth muscle relaxations to endothelium-derived NO. Further studies are required to correlate *in vitro* observations with the long term vascular effects of arsenic ingestion *in vivo* at levels found in contaminated drinking water, and to clarify conflicting reports that *in vivo* conversion to more toxic metabolites such as monomethylarsonous acid that may result in direct inhibition of eNOS ([@bib0195; @bib0120]). Possible iatrogenic effects of trivalent arsenic on vascular function also remain to be investigated given that arsenic trioxide is now widely used in the treatment of haematological conditions such as acute promyelocytic leukaemia ([@bib0090]).

Conflict of interest statement {#sec0105}
==============================

The authors declare that there are no conflicts of interest.

The work was supported by the British Heart Foundation (Grant No. PG/08/072/25474) and the School of Medicine, Cardiff University

![Effects of arsenite on EDHF-type relaxations in endothelium-intact iliac artery rings. (A) Concentration--response curves and original recordings showing that 100 μM arsenite, but not 30 μM, potentiated CPA-evoked EDHF-type relaxations after 30 min. (B) Exposure to 100 μM arsenite for 30 min also potentiated EDHF-type relaxations evoked by ACh. Rings were constricted by 1 μM phenylephrine (PE). *n* denotes the number of animals studied.](gr1){#fig0005}

![Concentration--response curves showing that exposure to 100 μM arsenite for 30 min did not affect endothelium-dependent relaxations evoked by CPA or ACh in the iliac artery in the absence of [L]{.smallcaps}-NAME/indomethacin. *n* denotes the number of animals studied.](gr2){#fig0010}

![Effects of arsenite on relaxation in aortic rings with intact endothelium. (A) EDHF-type relaxations were \<5% of induced tone so that endothelium-dependent relaxation in this vessel can be attributed to NO. (B) Concentration--relaxation curves for CPA and ACh constructed in the absence of [L]{.smallcaps}-NAME/indomethacin were unaffected by exposure to 100 μM arsenite for 30 min. *n* denotes the number of animals studied.](gr3){#fig0015}

![Inhibitory effects of (A) 2000 units/ml catalase, (B) 100 μM MnTMPyP, and (C) 100 μM apocynin on the potentiation of CPA-evoked EDHF-type relaxations by exposure to 100 μM arsenite for 30 min. *n* denotes the number of animals studied.](gr4){#fig0020}

![Endothelial ROS production in rabbit isolated aortic valve leaflets loaded with DHE in the presence of [L]{.smallcaps}-NAME/indomethacin. (A) Nuclear fluorescence increased following exposure to 100 μM arsenite for 90 min, but was unaffected by apocynin or arsenite in combination with apocynin. (B) Bar graphs confirming statistical significance. *n* denotes the number of animals studied.](gr5){#fig0025}

![Fluorescence studies of endothelium-denuded iliac artery and aortic rings loaded with DHE in the presence of [L]{.smallcaps}-NAME/indomethacin. (A) and (B) Images and bar graphs showing that neither artery type exhibited evidence of excess ROS production in the media of the vessel wall following exposure to 100 μM arsenite for 90 min. The adventitia of both vessels displayed autofluorescence, but its appearances were unaltered by exposure to arsenite. Scalebars identify the vessel lumen. *n* denotes the number of animals studied.](gr6){#fig0030}

![Effects of 90 min exposure to 100 μM arsenite on relaxation in endothelium-intact iliac artery rings. Data are presented as absolute reversal (left panels) and % reversal (right panels) of PE-induced constriction. (A) EDHF-type responses to ACh. (B) Responses to ACh with [L]{.smallcaps}-NAME/indomethacin omitted from the buffer. (C) Responses to MAHMA NONOate in the presence of [L]{.smallcaps}-NAME/indomethacin.](gr7){#fig0035}

###### 

Effects of exposure to arsenite for 30 min on endothelium-dependent relaxations to CPA and ACh in the iliac artery.

  CPA                                             *n*   pIC~50~                                                *R*~max~, %
  ----------------------------------------------- ----- ------------------------------------------------------ -------------
  Control                                         9     4.99 ± 0.07                                            94.4 ± 2.8
  Arsenite 100 μM                                       4.98 ± 0.10                                            91.6 ± 3.3
  [L]{.smallcaps}-NAME + indo                     6     4.76 ± 0.07                                            82.7 ± 3.9
  [L]{.smallcaps}-NAME + indo + arsenite 30 μM          4.85 ± 0.05                                            79.8 ± 3.3
  [L]{.smallcaps}-NAME + indo                     22    4.85 ± 0.05                                            82.1 ± 1.8
  [L]{.smallcaps}-NAME + indo + arsenite 100 μM         5.16 ± 0.08[\*\*\*](#tblfn0005){ref-type="table-fn"}   83.1 ± 1.7

  ACh                                             *n*   pEC~50~                                                *R*~max~, %
  ----------------------------------------------- ----- ------------------------------------------------------ -------------
  Control                                         12    7.32 ± 0.10                                            91.3 ± 2.2
  Arsenite 100 μM                                       7.52 ± 0.10                                            91.1 ± 2.3
  [L]{.smallcaps}-NAME + indo                     12    6.83 ± 0.09                                            72.7 ± 4.1
  [L]{.smallcaps}-NAME + indo + arsenite 100 μM         7.08 ± 0.09[\*\*\*](#tblfn0005){ref-type="table-fn"}   72.4 ± 4.0

Experiments were performed in the absence (control) and presence of [L]{.smallcaps}-NAME (300 μM) and indomethacin (10 μM). Potency (negative log IC~50~ or log EC~50~) and maximal responses (*R*~max~) are given as mean ± SEM. *n* denotes the number of animals studied.

*P* \< 0.001 compared with time-matched preparations not exposed to arsenite.

###### 

Effects of exposure to 100 μM arsenite for 30 min on endothelium-dependent relaxations to CPA and ACh in the aorta.

  CPA        *n*   pIC~50~       *R*~max~, %
  ---------- ----- ------------- -------------
  Control    6     4.73 ± 0.24   82.4 ± 1.7
  Arsenite         5.00 ± 0.12   78.1 ± 4.1

  ACh        *n*   pEC~50~       *R*~max~, %
  ---------- ----- ------------- -------------
  Control    8     7.09 ± 0.03   63.0 ± 1.2
  Arsenite         7.19 ± 0.07   69.5 ± 2.5

Potency (negative log IC~50~ or log EC~50~) and maximal responses (*R*~max~) are given as mean ± SEM. *n* denotes the number of animals studied.

###### 

Effects of catalase, MnTMPyP and apocynin on the potentiation of CPA-evoked EDHF-type relaxations in the iliac artery by 100 μM arsenite for 30 min.

  CPA                           *n*   pIC~50~                                                *R*~max~, %
  ----------------------------- ----- ------------------------------------------------------ -------------
  [L]{.smallcaps}-NAME + indo   9     4.92 ± 0.05                                            79.5 ± 2.3
  \+ Arsenite 100 μM                  5.21 ± 0.07[\*\*\*](#tblfn0020){ref-type="table-fn"}   81.0 ± 2.5
  \+ Catalase 2000 U ml^−1^           4.79 ± 0.05                                            82.2 ± 2.8
  \+ Arsenite + catalase              4.80 ± 0.04                                            77.9 ± 3.0
                                                                                             
  [L]{.smallcaps}-NAME + indo   8     4.68 ± 0.07                                            78.9 ± 2.8
  \+ Arsenite 100 μM                  5.05 ± 0.05[\*](#tblfn0010){ref-type="table-fn"}       84.1 ± 3.1
  \+ MnTMPyP 100 μM                   4.59 ± 0.07                                            73.3 ± 4.5
  \+ Arsenite + MnTMPyP               4.69 ± 0.10                                            70.7 ± 5.6
                                                                                             
  [L]{.smallcaps}-NAME + indo   14    4.99 ± 0.07                                            86.2 ± 1.9
  \+ Arsenite 100 μM                  5.31 ± 0.05[\*\*](#tblfn0015){ref-type="table-fn"}     83.1 ± 2.1
  \+ Apocynin 100 μM                  4.89 ± 0.07                                            78.7 ± 3.7
  \+ Arsenite + apocynin              5.04 ± 0.06                                            82.9 ± 3.1

All experiments were performed in the presence of [L]{.smallcaps}-NAME (300 μM) and indomethacin (10 μM). Potency (negative log IC~50~) and maximal responses (*R*~max~) are given as means ± SEM. *n* denotes the number of animals studied.

*P* \< 0.05 compared with time-matched controls.

*P* \< 0.01 compared with time-matched controls.

*P* \< 0.001 compared with time-matched controls.

###### 

Effects of exposure to 100 μM arsenite for 90 min on endothelium-dependent relaxations to ACh and direct relaxation to MAHMA NONOate in the RIA.

  ACh                                      *n*   pEC~50~
  ---------------------------------------- ----- -------------
  Control                                  7     7.11 ± 0.06
  Arsenite                                 7     7.37 ± 0.14
  [L]{.smallcaps}-NAME + indo              9     6.74 ± 0.09
  [L]{.smallcaps}-NAME + indo + arsenite   9     7.03 ± 0.13

  MAHMA NONOate                                     *n*   pEC~50~
  ------------------------------------------------- ----- -------------
  1 μM PE, [L]{.smallcaps}-NAME + indo              17    7.01 ± 0.11
  1 μM PE, [L]{.smallcaps}-NAME + indo + arsenite   11    7.02 ± 0.15
  0.1 μM PE, [L]{.smallcaps}-NAME + indo            6     7.39 ± 0.11

Potency (negative log EC~50~) is given as mean ± SEM. *n* denotes the number of animals studied.
